The patent waiver proposed by India and South Africa and supported by various other countries has been revised proposing the temporary waiver to be for at least three years. This revision comes amid the uncertainty regarding the effectiveness of the vaccine for children and against new variants and was aimed to narrow down the scope of the waiver.